Replies to post #65 on Equillium Inc (EQ)

[trademax42]

Right on. The study appeared to have used two groups of patients. I believe the first group was given the drug + supportive care, the second group only got the supportive care. No one in the first group (itolizumab arm) died while about 30% participants in the second group (control arm) sadly passed away.

Very robust outcomes, imo.

$EQ

Disclosure: all Imho only, do your own DD.